Maropitant for Dogs: Dosing and Uses

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Maropitant is a prescription antiemetic for dogs. It blocks the neurokinin-1 (NK1) receptor, the docking site for substance P, a signaling molecule that triggers the vomiting reflex in the brain. The drug is sold under the brand name Cerenia and as generic maropitant citrate. It is labeled to treat acute vomiting and to prevent vomiting caused by motion sickness. It is not a treatment for chronic vomiting that has no diagnosis, and it does not fix the underlying cause of a dog's illness. It stops the vomiting while a veterinarian works out why the dog is sick.

This article covers what maropitant does, how it is dosed by label, how the brand and generic compare, what side effects owners may see, and when vomiting needs a phone call or an exam rather than a pill.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

What Maropitant Is and What It Does

Maropitant citrate is a neurokinin-1 receptor antagonist. It works by occupying NK1 receptors in the central nervous system so that substance P cannot bind and set off the emetic (vomiting) cascade. Substance P is a neuropeptide released during many kinds of nausea and vomiting, including vomiting caused by chemotherapy, opioids, anesthesia, and motion. Blocking its receptor at the source shuts down the reflex rather than just sedating the dog or slowing the gut.

The drug was the first NK1 receptor antagonist developed specifically to treat and prevent vomiting in dogs [1]. It is given either as a subcutaneous injection at 1 mg/kg or as an oral tablet at 2 or 8 mg/kg depending on the indication [1]. The injectable is intended for subcutaneous use, not intravenous use, in routine practice.

Maropitant is not a gut motility drug and not an acid reducer. It does not coat the stomach, does not bind toxins, and does not treat the disease causing the vomiting. It reduces the vomiting itself.

Labeled Uses

Maropitant has two labeled uses in dogs.

Treatment of Acute Vomiting

The injectable form is labeled to treat acute vomiting, meaning vomiting that started recently and is not a long-standing pattern. In a randomized clinical trial of dogs with cisplatin-induced vomiting, maropitant given before chemotherapy prevented vomiting in 94.9% of dogs, compared with 4.9% of placebo-treated dogs [2]. When given after a vomiting event, maropitant reduced the number of later vomiting episodes compared with placebo [2]. That trial used cisplatin, a strong emetic, but the mechanism is the same for other causes of acute vomiting.

Prevention of Motion Sickness Vomiting

The oral tablet is labeled to prevent vomiting caused by motion sickness. This is the use most owners recognize: a dog that vomits in the car. The oral dose for this indication is higher than the injectable dose because oral absorption is lower. Absolute bioavailability is about 90.7% after subcutaneous injection but only 23.7% at the 2 mg/kg oral dose and 37.0% at the 8 mg/kg oral dose [1]. First-pass metabolism in the liver explains the difference [1].

How Maropitant Works: NK1 Receptor Antagonism

Vomiting is controlled by a cluster of nuclei in the brainstem called the vomiting center. Several inputs feed into it, including the chemoreceptor trigger zone, the vestibular system (balance and motion), and signals from the gut. Substance P is one of the key neurotransmitters at these sites, and it acts through NK1 receptors.

Maropitant binds NK1 receptors and prevents substance P from activating them. Because it works centrally rather than peripherally, it is effective against vomiting from many triggers at once. In a blinded crossover study using a low-dose cisplatin model, maropitant at 1 mg/kg eliminated vomiting in every treated dog, and ondansetron did the same, while placebo-treated dogs vomited an average of seven times [3]. The same study showed maropitant reduced nausea-associated behavior, not just the physical act of vomiting [3].

That distinction matters. Vomiting is visible. Nausea is not. A dog that licks its lips, drools, swallows hard, or hunches may be nauseated even if nothing comes up. Maropitant reduces both the vomiting and several signs of nausea in dogs [4].

Cerenia vs Generic Maropitant Citrate

Cerenia is the original brand of maropitant citrate, made by Zoetis. Generic maropitant citrate contains the same active ingredient and is available from other manufacturers. The active molecule is the same, and the labeled uses and doses are the same.

Practical differences owners may notice:

• Price. Generics are often less expensive than the brand. The size of the difference varies by pharmacy and by tablet strength.
• Tablet strengths. Cerenia tablets come in 16 mg, 24 mg, 60 mg, and 160 mg. Generic products may not offer every strength, so a veterinarian may need to adjust the tablet count to match the dog's weight.
• Flavoring. Brand tablets are flavored. Some generics are not, which matters for a dog that refuses pills.
• Packaging. Brand injectable is a 10 mg/mL solution in a multi-dose vial. Generic injectable products are similar but check the concentration on the label, because concentration errors cause dosing errors.

Whatever the product, the dose is calculated in milligrams per kilogram of body weight. A 160 mg tablet is not a dose. It is a tablet. The dose depends on the dog.

Dose Table

The doses below reflect the labeled uses. They are not a substitute for a veterinarian's calculation for a specific dog.

The injectable is for subcutaneous use. It is not labeled for intravenous administration in routine practice. If a dog needs intravenous antiemetic therapy, the veterinarian will choose a product and route appropriate to that setting.

The oral motion sickness dose is 8 mg/kg because oral absorption is poor. Giving the injectable dose by mouth would underdose the dog. Giving the oral motion sickness dose by injection would overdose the dog. The route and the dose are linked.

For the injectable, the labeled dose is 1 mg/kg once daily. Some studies used the same 1 mg/kg subcutaneous dose to prevent vomiting from opioids and other triggers [5][6][7]. In one study, maropitant at 1 mg/kg subcutaneously prevented vomiting in 100% of dogs given hydromorphone, compared with 0% of saline-treated dogs [7].

For oral prevention of opioid-induced vomiting, one study used 2.0 to 4.0 mg/kg orally two hours before hydromorphone and found no vomiting in any treated dog, compared with 25% of placebo dogs [8]. That dose range falls within labeled oral use for that indication.

How to Give Maropitant

Injectable

The injectable is given by subcutaneous injection, usually in the scruff or another loose-skinned area. A veterinarian or trained technician typically gives it. Owners who give injections at home should be shown the technique and the correct volume for their dog's weight.

One practical point: subcutaneous maropitant injection causes discomfort in a meaningful number of dogs. In one study, 48% of dogs showed discomfort after subcutaneous maropitant, compared with about 10% after metoclopramide and about 5% after saline [5]. In another, 64.5% of dogs showed discomfort after subcutaneous maropitant, compared with 21.4% after intramuscular dimenhydrinate and 7.1% after saline [9]. The injection can sting. A dog that yelps or pulls away is not necessarily having a reaction. It may just be the injection itself.

Oral Tablets

Oral tablets are given by mouth, usually two hours before travel for motion sickness. The tablet can be given with a small amount of food or placed directly in the mouth. Do not crush or split a tablet unless the veterinarian says to, because the tablet may be coated and the dose is based on the whole tablet.

For motion sickness, timing matters. Give the tablet about two hours before the car ride. In one study, oral maropitant given two hours before premedication significantly reduced vomiting and nausea compared with control [4].

What to Do If a Dose Is Missed

If a dose is missed, give it when you remember, unless it is almost time for the next dose. Do not double up. If the dog vomits shortly after taking an oral tablet, do not give another dose without asking the veterinarian, because it is not clear how much was absorbed.

Side Effects

Maropitant is generally well tolerated. The most common owner-visible issue is discomfort at the injection site after subcutaneous administration [9][5].

Other side effects reported in studies and on the label include:

• Drooling, lip licking, and swallowing. These are signs of nausea, and they can occur even when maropitant is given. In one study, oral maropitant reduced vomiting but not all signs of nausea in dogs given hydromorphone [8]. In another, nausea incidence was not significantly different between maropitant, dimenhydrinate, and control groups [9].
• Vomiting after the injection. Rare, but possible if the dog was already nauseated.
• Lethargy or sleepiness. Some dogs seem quieter after the injection, though this may reflect the underlying illness or the sedative drugs given at the same time.

If a dog shows hives, facial swelling, difficulty breathing, or collapse after maropitant, that is an emergency. Seek veterinary care immediately.

Which Dogs Should Not Receive Maropitant

Maropitant is not for every dog.

• Dogs with a known hypersensitivity to maropitant. Do not give it again.
• Dogs with chronic vomiting that has not been diagnosed. Maropitant treats the symptom, not the cause. Using it to suppress vomiting without a diagnosis can delay treatment for a foreign body, pancreatitis, toxin exposure, or another serious condition.
• Dogs with liver disease. Maropitant is metabolized in the liver, and dose adjustment may be needed. Discuss this with the veterinarian.
• Puppies under the labeled minimum age. Follow the label and the veterinarian's instruction.
• Dogs receiving other drugs that affect liver enzymes. See the interactions section.

Maropitant is not approved for cats in all regions. In the United States, the label is for dogs. Some regions have a feline approval, but that is a separate product decision and not a reason to use a dog product in a cat without veterinary direction.

Drug Interactions and Metabolism

Maropitant is metabolized in the liver by cytochrome P450 enzymes, including CYP3A. That matters because many other drugs use the same pathway.

Drugs that can interact with maropitant include:

• Other CYP3A substrates. If two drugs compete for the same enzyme, blood levels of one or both can rise. The veterinarian may adjust doses or choose a different drug.
• CYP3A inhibitors. Drugs that block CYP3A can slow maropitant clearance and increase its blood level.
• CYP3A inducers. Drugs that speed up CYP3A can lower maropitant levels and reduce its effect.

The pharmacokinetics of maropitant are nonlinear in the 2 to 8 mg/kg oral range, meaning that doubling the dose does more than double the blood level [1]. At high doses, the metabolic clearance mechanisms become saturated, and drug elimination is delayed [10]. In a 14-day study, dogs given 8 mg/kg orally once daily accumulated maropitant in plasma substantially more than dogs given 2 mg/kg, with an accumulation ratio of 4.81 at 8 mg/kg versus 2.46 at 2 mg/kg [10]. This is why the oral dose for motion sickness is not simply scaled up from the injectable dose and why repeated high oral doses deserve veterinary oversight.

One study examined morphine pharmacokinetics when combined with maropitant and found that maropitant did not prolong morphine elimination the way dexmedetomidine did [11]. That is reassuring for the common combination of maropitant and opioids in anesthesia, but it does not rule out interactions with every drug.

If a dog is on any long-term medication, tell the veterinarian before maropitant is added.

How Maropitant Compares With Other Antiemetics

Maropitant is one of several antiemetics used in dogs. The others include ondansetron, metoclopramide, and dimenhydrinate. They work through different receptors.

• Ondansetron blocks 5-HT3 receptors. In a low-dose cisplatin model, ondansetron and maropitant both eliminated vomiting in every treated dog [3]. In a preoperative study, oral maropitant was significantly better than oral ondansetron at preventing vomiting and nausea after hydromorphone, acepromazine, and glycopyrrolate [4].
• Metoclopramide blocks dopamine D2 receptors. In a morphine-induced vomiting study, maropitant prevented vomiting in 100% of dogs, metoclopramide in 62%, and saline in 29% [5]. In a parvoviral enteritis study, maropitant, ondansetron, and metoclopramide were equally effective at reducing the frequency and severity of vomiting over five days [12].
• Dimenhydrinate is an antihistamine used for motion sickness and preoperative nausea. In a study of dogs sedated with hydromorphone and dexmedetomidine, maropitant significantly reduced vomiting and retching, while dimenhydrinate did not show the same effect [9].

The choice depends on the trigger. For opioid-induced vomiting, maropitant has strong evidence. For chemotherapy-induced vomiting, maropitant has strong evidence [2]. For parvoviral enteritis, several antiemetics work, and the veterinarian may choose based on availability, cost, and the dog's condition [12].

Maropitant is not interchangeable with these drugs. Each has a different receptor target and a different side effect profile.

Evidence for Maropitant in Common Clinical Situations

Opioid and Anesthesia-Related Vomiting

Opioids are common premedications and often cause vomiting. Maropitant consistently reduces this.

• In dogs given hydromorphone, subcutaneous maropitant at 1 mg/kg prevented vomiting in 100% of dogs, compared with 0% of saline-treated dogs [7].
• In dogs given morphine, maropitant reduced the incidence of vomiting and retching compared with saline and sham acupuncture [13].
• In dogs given hydromorphone, acepromazine, and glycopyrrolate, oral maropitant given two hours before premedication reduced vomiting to 10%, compared with 62% in controls and 54% in ondansetron-treated dogs [4].
• In dogs given morphine and acepromazine, subcutaneous maropitant at 1 mg/kg prevented vomiting in 100% of dogs, compared with 62% for metoclopramide and 29% for saline [5].

Timing matters. In one study, maropitant given 15 minutes before hydromorphone significantly decreased vomiting, and given 30 minutes before, it prevented vomiting. Signs of nausea were significantly decreased only when maropitant was given 60 minutes before hydromorphone [6]. For the best effect, give maropitant at least 30 to 60 minutes before the trigger when possible.

Chemotherapy-Related Vomiting

Maropitant is well studied for chemotherapy-induced nausea and vomiting. In a randomized trial of 122 tumor-bearing dogs, maropitant given before cisplatin prevented vomiting in 94.9% of dogs, compared with 4.9% of placebo dogs [2]. Given after a vomiting event, maropitant reduced subsequent vomiting episodes and cut treatment failure from 56.4% to 5.3% [2].

For delayed vomiting after doxorubicin, oral maropitant at 2 mg/kg once daily for five days significantly reduced vomiting and diarrhea compared with placebo [14].

Postoperative Nausea and Vomiting

In geriatric dogs undergoing major surgery, a protocol including maropitant, famotidine, and fentanyl resulted in no vomiting, 3.8% nausea, 1.9% regurgitation, and 1.0% aspiration pneumonia [15]. That is a low incidence in a high-risk group.

In dogs undergoing ovariohysterectomy, preoperative maropitant reduced intraoperative isoflurane requirements and reduced signs of postoperative nausea and vomiting [16]. Lower isoflurane requirements mean the dog needs less anesthetic gas to stay asleep, which can be safer.

Parvoviral Enteritis

In dogs with parvoviral enteritis, maropitant at 1 mg/kg subcutaneously once daily reduced vomiting severity from the first day and vomiting numbers from the third day. It was as effective as metoclopramide and ondansetron [12]. This is a supportive treatment, not a cure for parvovirus. The dog still needs fluids and supportive care.

Motion Sickness

The oral tablet is labeled for motion sickness prevention. The 8 mg/kg oral dose is higher than the injectable dose because oral absorption is poor [1]. Give it about two hours before travel.

What Maropitant Does Not Do

Maropitant does not stop gastroesophageal reflux. In one study, maropitant prevented vomiting in anesthetized dogs but did not reduce the number of reflux events or the number of dogs with reflux [17]. If a dog has reflux, maropitant alone will not fix it.

Maropitant does not treat chronic vomiting without a diagnosis. In a case report of a dog with cyclic vomiting syndrome, vomiting did not respond to maropitant, ondansetron, or metoclopramide, and the diagnosis required extensive testing [18]. That is an unusual case, but it illustrates the point: when vomiting is chronic or atypical, the answer is diagnosis, not more antiemetic.

Maropitant does not treat the underlying disease. A dog with a foreign body, pancreatitis, kidney failure, or toxin exposure still needs treatment for that condition.

Maropitant and Diagnostic Testing

Maropitant is often given before sedation with alpha-2 agonists to reduce the risk of vomiting. A study in atopic dogs found that maropitant citrate altered intradermal test reactivity for histamine and positive allergens [19]. If a dog is scheduled for allergy testing, tell the veterinarian about any recent maropitant dose.

Limitations and When to Contact a Veterinarian

Maropitant is a symptom treatment. It does not replace a diagnosis. Contact a veterinarian if any of the following apply:

• Vomiting lasts more than 24 hours or keeps coming back after the maropitant wears off.
• The dog vomits blood or the vomit looks like coffee grounds.
• The dog is lethargic, weak, or collapsed.
• The dog has a swollen or painful abdomen.
• The dog may have eaten a foreign body, toxin, or human medication.
• The dog is a puppy, is very old, or has a chronic illness.
• The dog has diarrhea with blood, or diarrhea and vomiting together.
• The dog is not drinking or shows signs of dehydration such as tacky gums or skin that stays tented.
• The dog is already on other medications and you are unsure about interactions.
• The dog has liver disease or has had liver problems before.

Vomiting is a symptom, not a diagnosis. A dog that vomits once and then eats and acts normally may not need medication. A dog that vomits repeatedly, acts sick, or has other signs needs an exam.

Individual cases vary. A veterinarian who examines the dog can decide whether maropitant is appropriate, what dose to use, and whether other tests or treatments are needed.

Frequently Asked Questions

What is maropitant used for in dogs?

Maropitant is used to treat acute vomiting and to prevent vomiting caused by motion sickness in dogs. It is a prescription NK1 receptor antagonist that blocks substance P, a key trigger of the vomiting reflex.

What is the dose of maropitant for dogs?

The labeled injectable dose is 1 mg/kg once daily by subcutaneous injection for acute vomiting. The labeled oral dose for motion sickness prevention is 8 mg/kg once daily. A veterinarian calculates the exact dose for your dog's weight.

Is Cerenia the same as generic maropitant?

Yes. Cerenia is the brand name for maropitant citrate. Generic maropitant citrate contains the same active ingredient and is used at the same doses. The main differences are price, tablet strengths, and flavoring.

Can I give maropitant to my dog for chronic vomiting?

No, not without a diagnosis. Maropitant treats the symptom, not the cause. Chronic vomiting needs a veterinary workup to find out why the dog is vomiting before antiemetics are used long term.

How fast does maropitant work in dogs?

The injectable reaches peak plasma concentration about 45 minutes after subcutaneous dosing. Oral tablets peak later, around 1.7 to 1.9 hours depending on the dose. For prevention, give maropitant at least 30 to 60 minutes before the trigger when possible.

Does maropitant stop nausea or only vomiting?

Maropitant reduces both vomiting and several signs of nausea, including lip licking, drooling, and hard swallowing. It does not eliminate every sign of nausea in every dog.

Is maropitant safe for cats?

Maropitant is not approved for cats in all regions. In the United States, the label is for dogs. Do not give a dog product to a cat without veterinary direction.

What are the side effects of maropitant in dogs?

The most common side effect is discomfort at the injection site after subcutaneous administration. Some dogs show signs of nausea such as drooling or lip licking even after treatment. Serious reactions are rare.

Related Articles

• Cerenia Maropitant Anti-Nausea Dose: Motion Sickness Dosing Chart for Pets
• Cerenia Maropitant: Vomiting and Motion Sickness Dose Calculator
• Pharmacotherapy in Avian Medicine
• Hypothyroidism in Dogs: Weight Gain, Lethargy and Thyroxine Dosing
• Can Cats Eat Valerian Root? Sedative Effect and Dosing
• Ferret Care: Insulinoma hypoglycemia diet and prednisone dosing

Sources

1. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
2. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients.
3. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
4. Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
5. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
6. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs.
7. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone.
8. Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs.
9. Effectiveness of dimenhydrinate and maropitant in preventing preoperative emesis and nausea in healthy dogs sedated with hydromorphone and dexmedetomidine: a randomized, blinded trial.
10. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days.
11. Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane.
12. Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs.
13. Effects of maropitant, acepromazine, and electroacupuncture on vomiting associated with administration of morphine in dogs.
14. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs.
15. Low incidence of postoperative nausea, vomiting, regurgitation, and aspiration pneumonia in geriatric dogs receiving maropitant, famotidine, and fentanyl as part of an anesthesia protocol.
16. The effect of maropitant on intraoperative isoflurane requirements and postoperative nausea and vomiting in dogs: a randomized clinical trial.
17. Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone.
18. Diagnosis and management of presumptive cyclic vomiting syndrome in a dog: first report in veterinary medicine.
19. Influence of Maropitant Citrate on Pollen and Control Intradermal Test Reactivity in Atopic Dogs: A Randomised, Controlled, Blinded Trial.